快新聞／高端疫苗獲准在巴拉圭做第3期臨床試驗 估Q4取得期中分析數據
發布時間：2021/07/20 14:54:53
更新時間：2021/07/20 14:54:53
;%20}%20.cls-2%20{%20fill:%20%23fff;%20}%20.cls-2,%20.cls-3%20{%20fill-rule:%20evenodd;%20}%20.cls-3%20{%20fill:%20%236d6d6d;%20}%20%3c/style%3e%3cmask%20id='mask'%20x='0'%20y='0'%20width='42'%20height='42'%20maskUnits='userSpaceOnUse'%3e%3cg%20id='mask-2'%3e%3cpolygon%20id='path-1'%20class='cls-2'%20points='0%200%2042%200%2042%2042%200%2042%200%200'/%3e%3c/g%3e%3c/mask%3e%3c/defs%3e%3c!--%20Generator:%20Adobe%20Illustrator%2028.7.1,%20SVG%20Export%20Plug-In%20.%20SVG%20Version:%201.2.0%20Build%20142)%20--%3e%3cg%3e%3cg%20id='_圖層_1'%20data-name='圖層_1'%3e%3cg%20id='Web版'%3e%3cg%20id='_財經-首頁'%20data-name='財經-首頁'%3e%3cg%20id='social_FB'%3e%3cg%20id='Group-3'%3e%3cg%20class='cls-1'%3e%3cpath%20id='Fill-1'%20class='cls-3'%20d='M21,42C6.6,42,0,36.1,0,21.7S6.6,0,21,0s21,7.3,21,21.7-6.6,20.3-21,20.3Z'/%3e%3c/g%3e%3c/g%3e%3cpath%20id='Fill-4'%20class='cls-2'%20d='M23,34v-11.8h4l.6-4.6h-4.5v-2.9c0-1.3.4-2.2,2.3-2.2h2.4v-4.1c-.4,0-1.9-.2-3.5-.2-3.5,0-5.9,2.1-5.9,6.1v3.4h-4v4.6h4v11.8h4.7Z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
;%20}%20.cls-2%20{%20fill:%20%23fff;%20}%20.cls-2,%20.cls-3%20{%20fill-rule:%20evenodd;%20}%20.cls-3%20{%20fill:%20%236d6d6d;%20}%20%3c/style%3e%3cmask%20id='mask'%20x='0'%20y='0'%20width='42'%20height='42'%20maskUnits='userSpaceOnUse'%3e%3cg%20id='mask-2'%3e%3cpolygon%20id='path-1'%20class='cls-2'%20points='0%200%2042%200%2042%2042%200%2042%200%200'/%3e%3c/g%3e%3c/mask%3e%3c/defs%3e%3c!--%20Generator:%20Adobe%20Illustrator%2028.7.1,%20SVG%20Export%20Plug-In%20.%20SVG%20Version:%201.2.0%20Build%20142)%20--%3e%3cg%3e%3cg%20id='_圖層_1'%20data-name='圖層_1'%3e%3cg%20id='Web版'%3e%3cg%20id='_財經-首頁'%20data-name='財經-首頁'%3e%3cg%20id='social_line'%3e%3cg%20id='Group-3'%3e%3cg%20class='cls-1'%3e%3cpath%20id='Fill-1'%20class='cls-3'%20d='M42,21.7c0,14.4-6.6,20.3-21,20.3S0,36.1,0,21.7,6.6,0,21,0s21,7.3,21,21.7'/%3e%3c/g%3e%3c/g%3e%3cpath%20id='Fill-4'%20class='cls-2'%20d='M30.6,18.3c0,.1-.1.3-.3.3h-2.6v1h2.6c.1,0,.3.1.3.3v1c0,.1-.1.3-.3.3h-2.6v1h2.6c.1,0,.3.1.3.3v1c0,.1-.1.3-.2.3h-3.8c-.1,0-.3-.1-.3-.3v-5.9c0-.1.1-.3.3-.3h3.8c.1,0,.3.1.3.3v1ZM25.5,23.2c0,.1-.1.3-.3.3h-.9s0,0,0,0h0s0,0,0,0h0s0,0,0,0l-2.7-3.7v3.6c0,.1-.1.3-.3.3h-1c-.1,0-.3-.1-.3-.3v-5.9c0-.1.1-.3.3-.3h1.1s0,0,0,0h0s0,0,0,0h0s0,0,0,0c0,0,0,0,0,0l2.7,3.7v-3.5c0-.1.1-.3.3-.3h1c.1,0,.2.1.2.3v5.9ZM19,23.2c0,.1-.1.3-.3.3h-1c-.1,0-.3-.1-.3-.3v-5.9c0-.1.1-.3.3-.3h1c.1,0,.3.1.3.3v5.9ZM16.7,23.2c0,.1-.1.3-.3.3h0s-3.8,0-3.8,0c-.1,0-.3-.1-.3-.3v-5.9c0-.1.1-.3.3-.3h1c.1,0,.3.1.3.3v4.7h2.6c.1,0,.3.1.3.3v1ZM21.4,8.9c-7.4,0-13.4,5-13.4,11s4.8,10,11.2,10.9c.4,0,1,.3,1.2.7.1.3,0,.9,0,1.2,0,0-.2,1-.2,1.2,0,.3-.3,1.3,1.2.7,1.4-.6,7.7-4.6,10.5-7.9,1.9-2.2,2.9-4.4,2.9-6.8,0-6.1-6-11-13.4-11h0Z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
國內疫情趨緩，高端疫苗今發新聞稿證實，其於7月6日向巴拉圭醫藥法規主管機關，國家衛生監督局 （DINAVISA）提出第三期臨床試驗申請，經DINAVISA審查評估後，於台灣時間7月20日，正式取得第三期臨床試驗核准，可開始收案進行第三期人體臨床試驗。
高端疫苗說明，本項三期臨床試驗為高端疫苗與巴拉圭亞松森大學醫學院共同合作，試驗採免疫橋接設計與AstraZeneca（AZ）新冠肺炎疫苗進行比對性試驗，三期人體臨床試驗預計於今年第三季完成所有受試者（約1,000人）收案，並於今年第四季取得期中分析數據。
高端疫苗表示，本項臨床試驗於取得巴拉圭當地臨床的安全性與免疫原性比較數據後，將加速佈局中南美洲市場。
（民視新聞網／綜合報導）
;%20}%20.cls-2%20{%20fill:%20%23fff;%20}%20.cls-2,%20.cls-3%20{%20fill-rule:%20evenodd;%20}%20.cls-3%20{%20fill:%20%23ff681d;%20}%20.cls-4%20{%20mask:%20url(%23mask-1);%20}%20.cls-5%20{%20fill:%20none;%20stroke:%20%23c6c6c6;%20stroke-width:%201.3px;%20}%20%3c/style%3e%3cmask%20id='mask'%20x='0'%20y='12.3'%20width='17.3'%20height='13.9'%20maskUnits='userSpaceOnUse'%3e%3cg%20id='mask-2'%3e%3cpolygon%20id='path-1'%20class='cls-2'%20points='0%2012.3%2017.3%2012.3%2017.3%2026.3%200%2026.3%200%2012.3'/%3e%3c/g%3e%3c/mask%3e%3cmask%20id='mask-1'%20x='16.7'%20y='0'%20width='1.3'%20height='30'%20maskUnits='userSpaceOnUse'%3e%3cg%20id='mask-4'%3e%3cpolygon%20id='path-3'%20class='cls-2'%20points='16.7%200%2018%200%2018%2030%2016.7%2030%2016.7%200'/%3e%3c/g%3e%3c/mask%3e%3c/defs%3e%3c!--%20Generator:%20Adobe%20Illustrator%2028.7.1,%20SVG%20Export%20Plug-In%20.%20SVG%20Version:%201.2.0%20Build%20142)%20--%3e%3cg%3e%3cg%20id='_圖層_1'%20data-name='圖層_1'%3e%3cg%20id='Web版'%3e%3cg%20id='_財經-首頁'%20data-name='財經-首頁'%3e%3cg%20id='Hot_6-10'%3e%3cg%20id='topic'%3e%3cg%20id='topic_before'%3e%3cg%20id='Group-3'%3e%3cg%20class='cls-1'%3e%3cpath%20id='Fill-1'%20class='cls-3'%20d='M15.6,12.7c-.7-.5-1.7-.5-2.4,0L.7,22.8c-.8.7-1,1.9-.3,2.7.4.5,1,.7,1.5.7s.9-.1,1.2-.4l11.3-9.1,2.9,2.1v-4.9l-1.7-1.3Z'/%3e%3c/g%3e%3c/g%3e%3cg%20id='Group-6'%3e%3cg%20class='cls-4'%3e%3cline%20id='Stroke-4'%20class='cls-5'%20x1='17.3'%20y1='0'%20x2='17.3'%20y2='30'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
;%20}%20.cls-2%20{%20fill:%20%23fff;%20}%20.cls-2,%20.cls-3%20{%20fill-rule:%20evenodd;%20}%20.cls-3%20{%20fill:%20%23ff681d;%20}%20.cls-4%20{%20fill:%20none;%20stroke:%20%23c6c6c6;%20stroke-width:%201.3px;%20}%20%3c/style%3e%3cmask%20id='mask'%20x='0'%20y='0'%20width='1.3'%20height='30'%20maskUnits='userSpaceOnUse'%3e%3cg%20id='mask-2'%3e%3cpolygon%20id='path-1'%20class='cls-2'%20points='0%200%201.3%200%201.3%2030%200%2030%200%200'/%3e%3c/g%3e%3c/mask%3e%3c/defs%3e%3c!--%20Generator:%20Adobe%20Illustrator%2028.7.1,%20SVG%20Export%20Plug-In%20.%20SVG%20Version:%201.2.0%20Build%20142)%20--%3e%3cg%3e%3cg%20id='_圖層_1'%20data-name='圖層_1'%3e%3cg%20id='Web版'%3e%3cg%20id='_財經-首頁'%20data-name='財經-首頁'%3e%3cg%20id='Hot_6-10'%3e%3cg%20id='topic'%3e%3cg%20id='topic_after'%3e%3cpath%20id='Fill-1'%20class='cls-3'%20d='M16.7,9.8l-5.9.8c-.9.1-1.3,1.3-.7,1.9l1.4,1.3-4.8,4.7L.7,14v4.9l5.1,3.8c.8.6,1.9.5,2.6-.2l6-5.9.9.9c.7.7,1.8.3,2-.6l.8-5.8c.1-.8-.5-1.4-1.3-1.3'/%3e%3cg%20id='Group-5'%3e%3cg%20class='cls-1'%3e%3cline%20id='Stroke-3'%20class='cls-4'%20x1='.7'%20y1='0'%20x2='.7'%20y2='30'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
